PNS

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Retrieved on: 
Wednesday, September 21, 2022
Adult, Knee, Safety, OH, PNS, SPRINT, Risk, Population, Shoulder, Medtech, Erythema, SPR, Judgement, Therapy, Patient, Physician, Pain, Quality of life, Neck pain, GLOBE, Skin, Low back pain, NP-hardness, Chronic pain, Dentistry

CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to deliver pain relief for patients suffering from axial neck pain at the Pacific Spine Pain Society annual meeting in Las Vegas. This anonymized real-world data from patients who underwent commercial placement of the SPRINT® PNS System provides an important and insightful look at how PNS performs across a wider range of patients than might enroll in a controlled trial. This non-destructive treatment was delivered to efferent fibers in the cervical medial branch nerves. Based on the retrospective analysis, 83 percent of patients were responders, defined as at least a 50% reduction in pain and/or a clinically significant improvement in quality of life.

Key Points: 
  • CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to deliver pain relief for patients suffering from axial neck pain at the Pacific Spine Pain Society annual meeting in Las Vegas.
  • This non-destructive treatment was delivered to efferent fibers in the cervical medial branch nerves.
  • Sixty-day percutaneous PNS has emerged as a potential, non-destructive treatment that can be used for axial neck pain by targeting efferent fibers in the cervical medial branch nerves to produce comfortable cycling tension in core cervical musculature (e.g., multifidus).
  • The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of post-operative pain.

Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System

Retrieved on: 
Tuesday, September 6, 2022
Chronic pain, SPR, Safety, Medtech, Pain, Knee, OH, Physician, Shoulder, Therapy, Doctor of Philosophy, 2.0, Judgement, Erythema, Infection, Lead, Skin, NP-hardness, GLOBE, Movement, Risk, SPRINT, PNS, Low back pain, Patient, Dentistry

As a commercially-available treatment utilizing temporary peripheral nerve stimulation (PNS), the SPRINT PNS System harnesses flexible, robust, minimally-invasive leadswhich play an important role in the treatment of patients with chronic and acute pain.

Key Points: 
  • As a commercially-available treatment utilizing temporary peripheral nerve stimulation (PNS), the SPRINT PNS System harnesses flexible, robust, minimally-invasive leadswhich play an important role in the treatment of patients with chronic and acute pain.
  • The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.
  • Physicians should use their best judgment when deciding when to use the SPRINT PNS System.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.

JA Solar and PNS Expand Cooperation to 100MW in First Half of 2022

Retrieved on: 
Wednesday, August 3, 2022
PV, Carbon, JA Solar Holdings, Awareness, JA, Blue, PNS, Industry, Renewable energy

BEIJING, Aug. 3, 2022 /PRNewswire/ -- JA Solar, one of the largest manufacturers of photovoltaic (PV) modules in the world, recently announced that its cooperation with Power n Sun (PNS), a highly-experienced solar product distributor in the South Asia and Middle East regions, reached over 100MW in the first half of 2022.

Key Points: 
  • BEIJING, Aug. 3, 2022 /PRNewswire/ -- JA Solar, one of the largest manufacturers of photovoltaic (PV) modules in the world, recently announced that its cooperation with Power n Sun (PNS), a highly-experienced solar product distributor in the South Asia and Middle East regions, reached over 100MW in the first half of 2022.
  • The progress is remarkable considering the two companies only started their collaboration last year, recording exceptional volumes in the developing Middle East and South Asia PV markets.
  • With the purpose of promoting the application of distributed solar PV products in the target markets, the two companies established a cooperation relationship in 2021.
  • Through PNS's distribution channels, over 100MW of JA Solar's DeepBlue 3.0 PV modules were sold in the South Asia and the Middle East regions.

Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs

Retrieved on: 
Tuesday, August 2, 2022
Mayo Clinic, Society, DoD Inspector General Distinguished Service Award, Skin, GLOBE, American Academy, SPRINT, AAPM, Virginia Commonwealth University, Learning, Industry, Physician, CEO, Distinguished Service Award, North American Neuromodulation Society, Clinical professor, Judgement, Vanderbilt University, PNS, Risk, Chronic pain, Board, Therapy, OH, Safety, Catalog, ASRA, Low back pain, Erythema, Twilight anesthesia, Leadership, Medical Affairs Bureau, NANS, Publication, Patient, NP-hardness, Pain, SPR, Shoulder, Education, Medtech, Knee, Medical device, Dentistry

CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs.

Key Points: 
  • CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs.
  • In this role, he will provide insight to expand the understanding and use of peripheral nerve stimulation (PNS) in treating patients living with pain.
  • Dr. Huntoon has held pain medicine leadership roles at Virginia Commonwealth University, the Mayo Clinic, and Vanderbilt University.
  • SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option.

The Puzzles & Survival x The Walking Dead Crossover Event Has Officially Begun

Retrieved on: 
Tuesday, August 2, 2022
Dark, View, Interview, Breaking Bad, Alexandria Safe-Zone, AMC, Lord Dark Wind, Human, Social media, Survivor, Fear, Ride, Better Call Saul, Weapon, Vampire, PNS, IFC, Walking Dead, Multimedia, BBC America, Emmy Awards, Television, Negan, Survival, 61st Street, Savior, Sundance TV, Entertainment, Toy, Online shopping

GUANGZHOU, China, Aug. 2, 2022 /PRNewswire/ -- 37GAMES, the publisher of the zombie themed match-3 game Puzzles & Survival, is celebrating the game's second anniversary with the launch today of a global crossover event in collaboration with AMC's global smash hit television series The Walking Dead. With a total of ten in-game events over the month of August, there promises to be enough zombie survival mayhem for even the most diehard fans.

Key Points: 
  • GUANGZHOU, China, Aug. 2, 2022 /PRNewswire/ --37GAMES, the publisher of the zombie themed match-3 game Puzzles & Survival, is celebrating the game's second anniversary with the launch today of a global crossover event in collaboration with AMC's global smash hit television series The Walking Dead.
  • During this global collaboration event, fans will also be able to play as, and fight alongside, iconic characters such as Negan, Daryl Dixon, Rick Grimes, and Michonne.
  • Construct new buildings and obtain unique items to help turn back both the undead horde and threats from other survivors.
  • Lastly, players will be able to earn limited-edition The Walking Dead Sticker packs during the collaboration, as well as discover other in-game Easter eggs.

Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

Retrieved on: 
Thursday, July 14, 2022
Nervous system, Advantage Business Media, Technology, Intersect ENT, Chronic pain, Peripheral nerve stimulation, Sale, Hyperreflexia, SCS, IPG, Leadership, Johnson & Johnson, Spinal cord, PNS, Nerve, XENT, R, Patient, CEO, Heart, Brain, Physician, Director, Retirement, Division, Longevity, Pain, Intersection, FDA, Board, Growth, Pain management, Industry, D Magazine, NASDAQ, Management, Medical imaging, Medical device, Dentistry, Nalu, Medtronic, Hologic

CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer.

Key Points: 
  • CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer.
  • Mr. West remarked, "I am very excited and honored to be leading Nalu.
  • Mr. Fender added, "I am proud of the Nalu team and what we have accomplished to date.
  • Nalu, micro-IPG and the Nalu logo are trademarks of Nalu Medical, Inc.

SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022

Retrieved on: 
Thursday, July 14, 2022
Chronic pain, Itch, Physician, Safety, Knee, SPR, Judgement, Society, ASPN, NP-hardness, Low back pain, Treatment, PNS, Therapy, Risk, Erythema, Patient, Review, GLOBE, OH, Skin, Shoulder, Adhesive, Pain, Bandage, Quality of life, Trial of the century, Doctor of Philosophy, SPRINT, Medtech, Poultry, Dentistry

CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT PNS in treating chronic pain will be featured at the American Society of Pain & Neuroscience ( ASPN ) conference July 14-17.

Key Points: 
  • CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT PNS in treating chronic pain will be featured at the American Society of Pain & Neuroscience ( ASPN ) conference July 14-17.
  • There were no serious or unanticipated adverse events during this study, and the most common adverse events were mild skin irritation or pruritis (itching).
  • SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.

SPR Therapeutics Named a Top Workplace

Retrieved on: 
Sunday, June 26, 2022
The Plain Dealer, Patient, Adoption, Chronic pain, PNS, GLOBE, SPRINT, Shoulder, Low back pain, Pain, SPR, Risk, LLC, NP-hardness, OH, Culture, Medtech, Knee, Safety, Therapy, Poultry, Dentistry

CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer.

Key Points: 
  • CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer.
  • SPR Therapeutics developed the SPRINT PNS system to offer a minimally-invasive, 60-day implant specifically designed to deliver significant and sustained pain relief.
  • We are honored to receive this award and proud of the culture we have built at SPR, said SPR Therapeutics CEO Maria Bennett.
  • SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option.

Stimwave Announces Sale of Business

Retrieved on: 
Wednesday, June 15, 2022
General Health, Health, Neurology, Medical Devices, Hyperreflexia, PNS, Technology, Gibson, Dunn & Crutcher, Spinal cord, CEO, Court, Company, Brain, LLC, Growth, Physician, Pain, Chronic pain, Atos Information Technology Incorporated, United States bankruptcy court, Partnership, District, SCS, Patient, Chapter 11, Title 11, United States Code, Bankruptcy, HF, Sale, Pharmaceutical industry

Since 2020, the Company has successfully re-structured its entire team and business operations.

Key Points: 
  • Since 2020, the Company has successfully re-structured its entire team and business operations.
  • The new Stimwave team has worked closely with physicians, customers, professional societies, multiple governing agencies, and others to build a robust, trusted foundation.
  • Aure Bruneau, CEO of Stimwave commented: We are excited about the continued growth we have experienced over the last two years, during a challenging time.
  • To facilitate the sale of assets and the financing described above, Stimwave has filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Claims Development Management Earns Fourth NCQA UM Accreditation

Retrieved on: 
Tuesday, June 14, 2022
Practice Management, Insurance, Managed Care, General Health, Health, Professional Services, Health Insurance, Other Health, Risk management, PNS, Provider, Healthcare Improvement Scotland, IHI, Facebook, Program, UM, Hotel manager, CDM, LinkedIn, L.A. Care Health Plan, Information set, Accreditation, Quality assurance, Information, Patient, National Committee for Quality Assurance, Health, Primary care, Compliance, National Committee, Population, NCQA, Pain management, Institute, Recognition, Hospital, Medicine, Podiatry, Orthopedic surgery, Dermatology

Claims Development Management (CDM), a healthcare utilization management organization, established in 2013 and accredited in 2015 to deliver oversight to its clients under the National Committee for Quality Assurance (NCQA) https://www.ncqa.org guidelines, has earned its fourth Accreditation this May 3, 2022.

Key Points: 
  • Claims Development Management (CDM), a healthcare utilization management organization, established in 2013 and accredited in 2015 to deliver oversight to its clients under the National Committee for Quality Assurance (NCQA) https://www.ncqa.org guidelines, has earned its fourth Accreditation this May 3, 2022.
  • CDMs most recent and fourth NCQA UM Program Accreditation solidifies its commitment and dedication to the service level it delivers to its partners.
  • Claims Development Management (CDM) was established in 2013 to ensure utilization management decision-making through a variety of specialty networks.
  • NCQA can be found online at ncqa.org , on Twitter @ncqa , on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa .